Orexigen Therapeutics (NASDAQ: OREX) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Risk & Volatility

Orexigen Therapeutics has a beta of 2.3, meaning that its stock price is 130% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.73, meaning that its stock price is 173% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Orexigen Therapeutics and MacroGenics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orexigen Therapeutics 0 0 0 0 N/A
MacroGenics 0 2 9 0 2.82

MacroGenics has a consensus price target of $31.33, suggesting a potential upside of 62.60%. Given MacroGenics’ higher possible upside, analysts plainly believe MacroGenics is more favorable than Orexigen Therapeutics.

Institutional & Insider Ownership

34.7% of Orexigen Therapeutics shares are held by institutional investors. Comparatively, 85.8% of MacroGenics shares are held by institutional investors. 13.3% of Orexigen Therapeutics shares are held by insiders. Comparatively, 8.3% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Orexigen Therapeutics and MacroGenics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orexigen Therapeutics $33.71 million 0.59 -$24.52 million ($9.71) -0.12
MacroGenics $91.88 million 7.72 -$58.52 million ($4.50) -4.28

Orexigen Therapeutics has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Orexigen Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Orexigen Therapeutics and MacroGenics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Orexigen Therapeutics -192.65% -824.15% -68.53%
MacroGenics -1,526.55% -69.31% -58.09%


MacroGenics beats Orexigen Therapeutics on 9 of the 12 factors compared between the two stocks.

Orexigen Therapeutics Company Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

MacroGenics Company Profile

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company’s product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

Receive News & Ratings for Orexigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.